EDSA - Edesa Biotech, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Markham,
Canada
Type: Equity
EDSA price evolution
EDSA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.04 | $2.8 | $4.27 | |
| Short term investments | ||||
| Net receivables | $0.27 | $0.55 | $1.11 | $0.74 |
| Inventory | ||||
| Total current assets | $1.68 | $3.05 | $4.24 | $5.42 |
| Long term investments | $0.04 | $0.04 | $0.18 | |
| Property, plant & equipment | $0.02 | $0.04 | $0.06 | $0.08 |
| Goodwill & intangible assets | $2.1 | $2.13 | $2.15 | |
| Total noncurrent assets | $2.18 | $2.23 | $2.42 | |
| Total investments | $0.04 | $0.04 | $0.18 | |
| Total assets | $3.81 | $5.23 | $6.48 | $7.83 |
| Current liabilities | ||||
| Accounts payable | $1.81 | $2.32 | $2.09 | $1.91 |
| Deferred revenue | ||||
| Short long term debt | $0.04 | $0.06 | $0.08 | |
| Total current liabilities | $1.83 | $2.36 | $2.15 | $1.99 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.04 | $0.06 | $0.08 | |
| Total liabilities | $1.83 | $2.36 | $2.15 | $1.99 |
| Shareholders' equity | ||||
| Retained earnings | -$58.59 | -$57.63 | -$55.96 | -$54.1 |
| Other shareholder equity | -$0.24 | -$0.22 | -$0.23 | -$0.22 |
| Total shareholder equity | $2.87 | $4.32 | $5.84 | |
| (in millions $) | 31 Jan 2025 | 31 Dec 2023 | 30 Oct 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.36 | $7.09 | $7.84 | |
| Short term investments | ||||
| Net receivables | $0.27 | $0.63 | $1.26 | $3.3 |
| Inventory | ||||
| Total current assets | $1.68 | $6.44 | $9.09 | $12.09 |
| Long term investments | $0.17 | $0.17 | ||
| Property, plant & equipment | $0.02 | $0.1 | $0.03 | $0.11 |
| Goodwill & intangible assets | $2.18 | $2.28 | $2.38 | |
| Total noncurrent assets | $2.45 | $2.48 | $2.49 | |
| Total investments | $0.17 | $0.17 | ||
| Total assets | $3.81 | $8.89 | $11.58 | $14.58 |
| Current liabilities | ||||
| Accounts payable | $1.81 | $1.75 | $2.12 | $1.43 |
| Deferred revenue | ||||
| Short long term debt | $0.07 | $0.02 | $0.08 | |
| Total current liabilities | $1.83 | $1.82 | $2.14 | $1.46 |
| Long term debt | $0.02 | $0.02 | ||
| Total noncurrent liabilities | $0.02 | $0.04 | $0.07 | |
| Total debt | $0.09 | $0.02 | $0.1 | |
| Total liabilities | $1.83 | $1.84 | $2.18 | $1.53 |
| Shareholders' equity | ||||
| Retained earnings | -$58.59 | -$52.42 | -$44.04 | -$26.5 |
| Other shareholder equity | -$0.24 | -$0.21 | -$0.21 | -$0.21 |
| Total shareholder equity | $7.05 | $9.39 | $13.06 | |
| (in millions $) | 31 Jan 2025 | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.9 | $1.18 | ||
| Selling, general & administrative | $1.04 | $1.04 | ||
| Total operating expenses | $1 | $1.93 | $2.22 | |
| Operating income | -$1.93 | -$2.22 | ||
| Income from continuing operations | ||||
| EBIT | -$1.67 | -$1.86 | ||
| Income tax expense | $0 | |||
| Interest expense | $0.01 | |||
| Net income | ||||
| Net income | -$0.96 | -$1.67 | -$1.86 | |
| Income (for common shares) | -$1.67 | -$1.86 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.33 | |||
| Cost of revenue | $0.02 | |||
| Gross Profit | $0.31 | |||
| Operating activities | ||||
| Research & development | $4.79 | $13.34 | $17.95 | $3.33 |
| Selling, general & administrative | $4.43 | $5.04 | $5.73 | $3.38 |
| Total operating expenses | $9.22 | $18.37 | $23.68 | $6.71 |
| Operating income | -$9.22 | -$18.37 | -$23.68 | -$6.4 |
| Income from continuing operations | ||||
| EBIT | -$8.37 | -$17.55 | -$13.34 | -$6.36 |
| Income tax expense | $0 | $0 | $0 | $0 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$8.37 | -$17.55 | -$13.34 | -$6.36 |
| Income (for common shares) | -$8.37 | -$17.55 | -$13.34 | -$6.36 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1.67 | -$1.86 | -$1.68 | |
| Operating activities | ||||
| Depreciation | $0.05 | $0.05 | $0.05 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.11 | $0.15 | $0.18 | |
| Total cash flows from operations | -$0.86 | -$1.66 | -$1.41 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.11 | $0.24 | $0.31 | |
| Net borrowings | -$0.03 | |||
| Total cash flows from financing | $0.59 | $0.11 | $0.21 | $0.31 |
| Effect of exchange rate | -$0.03 | -$0.01 | -$0.02 | $0.01 |
| Change in cash and equivalents | -$4.32 | -$0.76 | -$1.47 | -$1.09 |
| (in millions $) | 31 Jan 2025 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$8.37 | -$17.55 | -$13.34 | |
| Operating activities | ||||
| Depreciation | $0.18 | $0.12 | $0.12 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.25 | $2.26 | $3.2 | |
| Total cash flows from operations | -$6.64 | -$12.28 | -$13.66 | |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.01 | ||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.83 | $11.63 | $14.17 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.59 | $4.83 | $11.63 | $14.17 |
| Effect of exchange rate | -$0.03 | $0.08 | -$0.09 | $0.12 |
| Change in cash and equivalents | -$4.32 | -$1.73 | -$0.75 | $0.63 |
News
Fundamentals
| Market cap | $7.18M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 3.25M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.91 |
| Quick ratio | N/A |